Event Registration
April 2, 2025, 4:30 PM CEST | 3:30 PM (BST)
10:30 AM ET (New York)
(Convert this to your time zone)
Conventional preclinical models often fail to evaluate antibody-based therapeutics, as they do not reflect crucial aspects of human physiology, forcing drug developers to adopt cautious and complex strategies. JAX's next-generation humanized models offer a solution by faithfully reproducing human physiology and pathology. These models enable more accurate predictions of biologic drug candidate performance, providing more predictive preclinical PK data.
Join our upcoming virtual symposium to explore how JAX's humanized models enable rational selection of the best lead therapeutic candidates, with equivalent or better predictive ability than nonhuman primates for human pharmacokinetics. The symposium will consist of three 20-minute presentations. Details are listed below.
Join us as we discuss:
This virtual event is complimentary.
No fees will be charged for registering.
|
Opening Remarks and Introduction Adriano Flora, Ph.D. Director, Business Development – Europe The Jackson Laboratory |
|
Humanized FcRn mouse model for evaluating PK and allometric scaling Monika Gajewska, Ph.D. M&S Group, PK Sciences Novartis Pharma AG |
|
Humanized FcRn mouse model for evaluating PK and allometric scaling Michael Kiffe Ph.D. Director PK Sciences / Translational Medicine Novartis Pharma AG |
|
Leveraging FcRn Transgenic Mice (tg32) for Drug Discovery of Therapeutic Antibodies Martin Lechmann Ph.D. DMPK/PD Project Lead (DPL) Biologics Roche Diagnostics GmbH |
|
Biology-Guided Design of Human Albumin Fusions – From Cross Species Binding Differences to Studies in Transgenic Mouse Models Jan Terje Andersen, Ph.D. Professor in Biomedical Innovation University of Oslo |
